Is compounded semaglutide still legal in 2026? A plain-English answer
The short version: sometimes, for specific medical reasons, but 'because it's cheaper' is no longer one of them. What changed when the FDA shortage ended, whether you can still get compounded GLP-1, and the questions that separate a legitimate program from a risky one.
By WeighedHealth Editorial
3 min readUpdated
- Late 04
- tirzepatide shortage declared resolved
- Early 05
- semaglutide shortage declared resolved
- 0
- FDA warning letters, September 2025
- Patient-specific
- the only remaining basis to compound
Jump to section
What changed
For about two years, the cheapest way to get a GLP-1 was a compounded version. Pharmacies could legally copy semaglutide and tirzepatide because both were in official FDA shortage, and federal rules allow compounding of drugs on the shortage list. Prices of roughly $150 to $300 per month were common.
That window has largely closed. The FDA declared the tirzepatide shortage resolved in late 2024 and semaglutide in early 2025, and the grace periods that let compounders keep producing wound down around mid-2025 [1]. Once a drug is off the shortage list, the broad legal basis for mass-compounding it disappears. Enforcement followed: the FDA issued dozens of warning letters (58 in a single September 2025 action) to firms marketing compounded products as equivalent to the brand, the FTC took action over misleading advertising, and on April 30, 2026 the FDA proposed permanently barring bulk 503B compounding of these molecules [2].
So can you still get it at all?
Yes, but narrowly. Compounding did not become illegal; it returned to its normal, limited role. A licensed pharmacy can still compound a patient-specific prescription when there is a documented medical reason the commercial product will not work: a genuine allergy or intolerance to an inactive ingredient, or a dose not commercially available for a specific clinical need.
What is no longer valid is simple cost. 'The brand is expensive, so make me a cheaper copy' is exactly the rationale the new posture removes. If a program is still selling compounded semaglutide as a routine budget alternative to Wegovy for anyone who signs up, that is the signal to ask hard questions: under what specific rule are you compounding this for me, which pharmacy dispenses it and is it licensed in my state, and is this patient-specific or a stock product made in bulk?
The flip side: branded access got better
The same period that closed the compounding loophole also lowered branded prices. Manufacturer direct-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) cut cash prices, and a Medicare GLP-1 Bridge program began July 1, 2026, bringing a lower copay to eligible enrollees. For many people, the branded drug through a direct-pay channel is now closer in price to what compounded used to cost, without the legal ambiguity.
The regulatory picture is genuinely confusing because it changed in stages and interacts with state law. WeighedHealth maintains a detailed explainer of the compounded-versus-branded legal status after the shortage removal, and a state-by-state table of GLP-1 laws, Medicaid coverage, and 503A compounding status.
Sources
Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss · U.S. Food and Drug Administration, 2025
- Human Drug Compounding · U.S. Food and Drug Administration, 2026
- Compounded vs branded GLP-1: legal status after FDA shortage removal (2026) · WeighedHealth, 2026
- GLP-1 laws and coverage by state (2026) · WeighedHealth, 2026
People also ask
Can you still get compounded semaglutide in 2026?
Yes, but narrowly. Compounding did not become illegal; it returned to its normal, limited role. A licensed pharmacy can still compound a patient-specific prescription when there is a documented medical reason the commercial product will not work, for example a genuine allergy to an inactive ingredient, or a dose not commercially available. What is no longer valid is compounding simply because the brand is expensive.
Why did compounded GLP-1 become restricted?
Because the legal basis disappeared. Federal rules allow compounding of drugs on the FDA shortage list, and semaglutide and tirzepatide were both in shortage from roughly 2022 to 2024 and 2025. Once the FDA declared the shortages resolved and grace periods ended, the broad basis for mass-compounding them ended too, followed by FDA warning letters and an FTC action.
Is branded GLP-1 now cheaper than it used to be?
For many people, yes. The same period that closed the compounding loophole also lowered branded prices: manufacturer direct-pay programs (NovoCare, LillyDirect) cut cash prices, and a Medicare GLP-1 Bridge program began July 1, 2026, lowering the copay for eligible enrollees. Branded through a direct-pay channel is now closer in price to what compounded used to cost, without the legal ambiguity.
Related reads
What a GLP-1 program actually costs in 2026, and the one number nobody advertises
The sticker price you see is almost never the price you pay. Here is how to read a GLP-1 telehealth quote (platform fee, medication, and labs) before you hand over a card, and why the all-in monthly cost is the only figure that matters.
Compounded GLP-1 in 2026: the complete legal map (post-503B rule)
What 'compounded' actually means, where the law stands after the April 2026 FDA rule, what's still legitimate, what isn't, and how to read a program's compliance posture in 10 minutes.
Wegovy cost without insurance in 2026: cheapest legitimate paths
Wegovy's pharmacy list price is ~$1,349 per month. For uninsured patients, the cheapest legitimate paths in 2026 are NovoCare self-pay at $499/month, transitioning to oral orforglipron at $149/month when prescriber agrees, or compounded semaglutide (a narrowing legal grey zone). Here are the actual options and what's changing.